Navigation Links
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Date:10/9/2007

Phase 2 Drug Candidate Protects the Ocular Surface Following Exposure to

Controlled Adverse Environment, Reduces Dry Eye Symptoms

LAGUNA HILLS, Calif., Oct. 9 /PRNewswire/ -- Alacrity Biosciences today announced that its dry eye treatment, ALTY-0501, demonstrated statistically significant advantages over vehicle in its ability to control signs and symptoms of dry eye in a Phase 2 study.

The Phase 2 study utilized the controlled adverse environment (CAE) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. Patients were randomized to receive ALTY-0501 or its vehicle four times each day over the course of a 56 day study.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores following CAE exposure for fluorescein staining of the total cornea-a measure of damage to the ocular surface-than those who received vehicle (p < 0.05) on day 28. Statistically significant differences from vehicle were also observed with total corneal and conjunctival staining (p < 0.05), superior corneal staining (p < 0.001) and nasal conjunctival staining (p < 0.05).

ALTY-0501 also demonstrated statistically significant advantages compared to vehicle in the patient diary scores measuring the severity of dry eye symptoms over the 56-day study period. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p < 0.0001), stinging (p < 0.0001), and grittiness (p < 0.0001) in the active treated group.

"We have strong evidence that ALTY-0501 can help control patient signs and symptoms by maintaining the epithelial barrier on the surface of the eye," said David F. Power, Alacrity's president and CEO. "We plan to discuss the Phase 2 data and confirm our Phase 2b/3 strategy with the FDA in the fourth quarter of 2007. Our in
'/>"/>

SOURCE Alacrity Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... 3, 2015 Your doctor has recommended surgery ... for the best possible outcome. Your orthopaedic foot and ... and now there,s a three-part online series ... the American Orthopaedic Foot & Ankle Society (AOFAS) ... avoid complications and heal as quickly as possible. ...
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... 1, 2011 PTC Therapeutics, Inc. (PTC) today announced ... of ataluren, an investigational new drug, in adults with ... Respiratory Journal . The published three-month data showed that ... chloride channel activity, CF-related cough and positive trends in ...
... READING, England and BEDMINSTER, N.J., June 30, 2011 ... Inc., today announced that the U.S. Food and Drug ... the management of breakthrough pain in cancer patients 18 ... and who are tolerant to opioid therapy for their ...
Cached Medicine Technology:Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 2Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 3Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 4Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 5Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 2FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 3FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 4FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 5FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 7FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 8
(Date:8/4/2015)... ... August 04, 2015 , ... Please join us for ... on Sunday, September 20th at Oneida Shores Park in Brewerton, NY. , Doris ... ruptured brain aneurysm at the young age of 59. Her family and friends have ...
(Date:8/4/2015)... ... August 04, 2015 , ... Following last month’s successful rollout of ... of Cath Lab Accreditation in an Academic Setting, and The Importance of PVI Accreditation. ... taped during the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions ...
(Date:8/3/2015)... ... ... pace of the economic recovery since the 2008 has been subject to much debate, the ... last six years. Unemployment has dropped from a 2009 high of 10 percent to 5.9 ... 2014, the U.S. stock market is at an all time high, and interest rates at ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Web SEO Master offers the most affordable web ... same business problem - making the most out of their dollar. Every company that ... It is crucial for existence. But not only does a start up need to ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Representatives with ... service on its website. , “Our ‘Ask a Nutritionist’ feature on our website is ... eat healthily,” said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health ...
Breaking Medicine News(10 mins):Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3
... with prostate cancer can improve their outcomes if they walk ... diagnosis, according to a recent study in Cancer Research ... "It appears that men who walk briskly after ... disease," said lead researcher Erin Richman, Sc.D., a research associate ...
... NEW YORK (May 23, 2011) -- Patients with ... clinical research study comparing two medications -- quetiapine ... and lithium, the gold-standard mood stabilizer. NewYork-Presbyterian ... sites nationally -- and the only site in ...
... 24, 2011For every year a person is homeless, the odds of ... to a report by St. Michael,s Hospital and Street Health. ... the lack of a health card, often because it has been ... in the journal Open Medicine , www.openmedicine.ca/article/view/368/407 , is ...
... May 24, 2011 The latest episode in ... " Global Challenges/Chemistry Solutions ," focuses on new ... are infected with an antibiotic-resistant bacterium that,s become ... This "superbug" is called methicillin-resistant Staphylococcus aureus, or ...
... , TUESDAY, May 24 (HealthDay News) -- Exercising ... why residents of Minneapolis-St. Paul find their city is now ... Every year, the American College of Sports Medicine (ACSM) ranks ... States, using the American Fitness Index (AFI). Although kicking the ...
... that their incomes start to rise not decline ... place says a Queen,s University School of Medicine professor. ... toward a Canadian-style system is feeble," says Jacalyn Duffin, ... medicine. "Physicians, incomes grew more quickly than those of ...
Cached Medicine News:Health News:Brisk walking could improve prostate cancer outcomes 2Health News:New study aims to improve long-term treatment for patients with bipolar disorder 2Health News:No health card means no family doctor for many homeless people 2Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Twin Cities Take Top Ranking for Healthy Living 2
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Active Cath is a latex, self-adhering, one piece catheter designed for extended wear. It combines a shortened latex sheath with a wide adhesive seal....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Medicine Products: